This document is a published patent application from the USPTO, not a rule or guidance with direct compliance obligations. It describes compositions comprising extracts from specific fungi (Agaricus blazei, Grifola frondosa, and Hericium erinaceus) that are claimed to prevent coronavirus infections by interfering with the interaction between the Spike S1 protein and ACE2.

While this is a patent application and not a regulatory mandate, companies involved in pharmaceutical research and development, particularly those working on antiviral therapies or treatments for coronavirus infections, should be aware of this disclosure. It highlights potential therapeutic avenues and intellectual property related to fungal extracts for infectious disease prevention. No immediate compliance actions are required for regulated entities based solely on this patent application publication.